Literature DB >> 31009793

Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes.

Karl Björkström1, Stefan Franzén2, Björn Eliasson3, Mervete Miftaraj2, Soffia Gudbjörnsdottir3, Ylva Trolle-Lagerros4, Ann-Marie Svensson3, Hannes Hagström5.   

Abstract

BACKGROUND & AIMS: Type 2 diabetes is a risk factor for development of cirrhosis and hepatocellular carcinoma. However, risk factors that identify persons with the highest risk for these outcomes are missing from unselected, population-based cohorts.
METHODS: The National Diabetes Register contains data on about 90% of persons in Sweden with type 2 diabetes. In this cohort study, persons with type 2 diabetes listed in the National Diabetes Register were compared with 5 individuals from the general population (controls), matched for age, sex, and county. In total, 406 770 persons with type 2 diabetes and 2 033 850 controls were included and followed for 21 596 934 person-years. We used population-based registers to determine the incidence of severe liver disease, defined as a diagnosis of hepatocellular carcinoma, cirrhosis, decompensation, liver failure and/or death due to liver disease during follow up. Cox regression was performed to estimate the risk of severe liver disease and to examine risk factors in persons with type 2 diabetes.
RESULTS: Risk for severe liver disease was increased in patients with type 2 diabetes compared to controls (hazard ratio, 2.28; 95% CI, 2.21-2.36). Risk factors associated with severe liver disease in persons with type 2 diabetes were higher age, male sex, hypertension, higher body mass index, lower glomerular filtration rate, microalbuminuria, and smoking. Statins were associated with a decreased risk of severe liver disease.
CONCLUSIONS: Persons with type 2 diabetes have an increased risk for severe liver disease. Knowledge of risk factors can be helpful in identifying persons with type 2 diabetes who have a high risk for severe liver disease.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HCC Risk; NAFLD; Obesity; T2DM

Mesh:

Substances:

Year:  2019        PMID: 31009793     DOI: 10.1016/j.cgh.2019.04.038

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  16 in total

Review 1.  The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Authors:  Hui Cao; Xiaosong Chen; Zhijun Wang; Lei Wang; Qiang Xia; Wei Zhang
Journal:  Cell Death Discov       Date:  2020-06-19

2.  NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse.

Authors:  Jose D Debes; Andre Boonstra; Robert J de Knegt
Journal:  Hepatology       Date:  2020-03-04       Impact factor: 17.425

3.  The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018.

Authors:  Ji Cheol Bae; Lauren A Beste; Kristina M Utzschneider
Journal:  Endocrinol Metab (Seoul)       Date:  2022-06-21

Review 4.  The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Authors:  Hui Cao; Xiaosong Chen; Zhijun Wang; Lei Wang; Qiang Xia; Wei Zhang
Journal:  Cell Death Discov       Date:  2020-06-19

5.  Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.

Authors:  Helen Jarvis; Dawn Craig; Robert Barker; Gemma Spiers; Daniel Stow; Quentin M Anstee; Barbara Hanratty
Journal:  PLoS Med       Date:  2020-04-30       Impact factor: 11.069

Review 6.  Mechanisms Underlying Hepatocellular Carcinoma Progression in Patients with Type 2 Diabetes.

Authors:  Tingting Shi; Hideki Kobara; Kyoko Oura; Tsutomu Masaki
Journal:  J Hepatocell Carcinoma       Date:  2021-02-11

7.  Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank.

Authors:  Federica Tavaglione; Antonio De Vincentis; Oveis Jamialahmadi; Roberta Pujia; Rocco Spagnuolo; Antonio Picardi; Susanna Morano; Luca Valenti; Stefano Romeo; Umberto Vespasiani-Gentilucci
Journal:  JHEP Rep       Date:  2021-03-02

8.  Lack of awareness of liver organ damage in patients with type 2 diabetes.

Authors:  Stefano Ciardullo; Tommaso Monti; Gianluca Perseghin
Journal:  Acta Diabetol       Date:  2021-01-26       Impact factor: 4.280

9.  Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience.

Authors:  Ioan Sporea; Ruxandra Mare; Alina Popescu; Silviu Nistorescu; Victor Baldea; Roxana Sirli; Adina Braha; Alexandra Sima; Romulus Timar; Raluca Lupusoru
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

10.  Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis.

Authors:  Adrian T Billeter; Philip C Müller; Thomas Albrecht; Stephanie Roessler; Moritz Löffler; Anastasia Lemekhova; Arianeb Mehrabi; Beat P Müller-Stich; Katrin Hoffmann
Journal:  J Gastrointest Surg       Date:  2020-05-06       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.